Abstract
Objectives To automate subarachnoid hemorrhage volume (SAHV) calculation (SAHVAI-SAHV Artificial Intelligence) and create 3D volumetric images (SAHVAI-3D) using non-contrast head CT (NCCT) imaging data in aneurysmal subarachnoid hemorrhage (SAH) patients. We also defined SAHVAI-4D, representing SAHV over time. The aim was to compare automated SAHVAI volumes to manual SAHV methods and computation times, explore these imaging biomarkers’ potential in identifying at-risk brain regions for delayed cerebral ischemia (DCI), and explore potential insights in future neurotherapeutic interventions for SAH patient recovery.
Methods A training set of 10 consecutive aneurysmal SAH cases was used to manually compute SAHV, SAHVAI-3D, and SAHVAI-4D, involving 92 non-contrast CT scans (182 slices each). The SAHVAI deep learning (DL) algorithm generated automated SAHV values in cubic centimeters (cc). For both SAHVAI and manual evaluations, a 3D SAH brain map was created for each patient. Blood volumetric outputs were analyzed and compared to neurological outcomes at discharge, including DCI events, symptomatic vasospasm (sVSP), and areas with the thickest SAH blood concentration.
Results SAHVAI quantified SAH blood volume (SAHV) in average of 6.7 seconds per scan, significantly faster than the manual method, which took over 60 minutes per scan (Fisher’s exact test, P value <0.001). SAHVAI demonstrated an accuracy of 99.8%, a Dice score of 0.701, a false positive rate of 0.0005, and a negative predictive value of 0.999. The mean absolute error between SAHVAI and manual methods was 5.67 ml. The SAHVAI-3D brain map and total SAHV at admission were strongly associated with neurological outcomes, inversely with Glasgow coma scale (R2=0.23, p=0.017) and directly with length of hospital stay (R2=0.175, p=0.004), especially in regions with dense blood concentration.
Conclusion SAHVAI-3D and SAHVAI-4D brain mapping techniques represent innovative imaging biomarkers for SAH. These advancements enable rapid evaluation and targeted interventions, potentially improving patient care in SAH management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of THE MAYO CLINIC waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
